Overview
This test assists in the diagnosis of autoimmune myasthenia gravis (MG) with acetylcholine receptor (AChR) antibodies. This is the first-line test in our MG antibody panel.
Test Code: | AChR RIPA |
Methodology: | In-house radioimmunoprecipitation |
Validation: | Laboratory developed test (LDT) |
Requirements
Specimen type | Serum |
Minimum volume | 0.5 mL |
Preferred volume | 3 mL |
Rejection criteria | Grossly hemolytic, lipemic, or icteric. If the sample arrives at room temperature. |
Specimen
Specimen collection | No patient preparation is required for sample collection. |
Specimen handling | Centrifuge SST tubes at 1800 - 2200 x g for 10-15 minutes |
specimen stability | Serum samples may be stored: |
Performance
Testing frequency | Once per week (2-day procedure) |
Turnaround time | 2-8 days |
Reference range | Negative: 0.0 – 0.2 nmol/L |
Additional Information
- This test was developed and its performance determined by Neurocode USA Inc. It has not been cleared or approved by the Food and Drug Administration.
- Please indicate if patients are on immunomodulating treatments as these may interfere with testing.
- Causal antibodies cannot be identified in about 10% of MG cases. Therefore, a positive result is specific for the diagnosis of AChR ab myasthenia gravis (MG), but a negative result does not rule out an MG diagnosis.
![section background image](https://neurocode.com/wp-content/themes/bigdrop-theme/dist/images/featured-bg.jpg)
Order Acetylcholine Receptor Antibodies by Radioimmunoprecipitation (AChR RIPA) Test
Reach out to our specialists today to start the ordering process.
Order Test